Promosome is dedicated to the development of best in class therapeutic proteins for the treatment of a broad spectrum of diseases and conditions. The company’s proprietary mRNA engineering technology exploits features of the natural translation process in both prokaryotic and eukaryotic cells to produce proteins that are safer and more effective at lower cost.
By optimizing ribosome recruitment, eliminating false starts in translation initiation, and ensuring message stability in both eukaryotic and prokaryotic cells, Promosome’s technology increases the yield, quality, and stability of therapeutic proteins while minimizing the risk of negative clinical outcomes associated with synonymous mutations.
The technology platform that Promosome has developed to advance its proprietary therapeutic pipeline has wide applicability for a range of indications in immunology, rheumatology, oncology, cardiology, dermatology and neurology and can be out-licensed for an extensive range of non-competing biotherapeutic and bioindustrial applications.
Promosome technologies enhance protein synthesis by taking advantage of several features of the natural mRNA translation process.
Promosome seeks partners for licensing arrangements to produce biotherapeutic proteins. Contact us to discuss the possibilities.
Our innovative technologies will be new to many in the industry. We know there will be questions.